DYSFUNCTIONAL CD39\(^{\text{POS}}\) REGULATORY T CELLS AND ABERRANT CONTROL OF T HELPER TYPE 17 CELLS IN AUTOIMMUNE HEPATITIS

Short title: CD39\(^{\text{POS}}\) REGULATORY T CELLS IN AUTOIMMUNE HEPATITIS

Authors: Charlotte R. Grant\(^{1}\), Rodrigo Liberal\(^{1,2}\), Beth S. Holder\(^{1}\), John Cardone\(^{1}\), Yun Ma\(^{1}\),

Simon C. Robson\(^{3}\), Giorgina Mieli-Vergani\(^{1,4}\), Diego Vergani\(^{1}\), Maria Serena Longhi\(^{1,3}\).

\(^{1}\)Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, UK
\(^{2}\)Faculty of Medicine, University of Porto, Porto, Portugal
\(^{3}\)Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
\(^{4}\)Paediatric Liver, GI & Nutrition Centre, King’s College London School of Medicine at King’s College Hospital, London, UK

KEYWORDS: adenosine; ATP; liver inflammation; Treg

Grant Support: CR Grant is supported by an Alex P Mowat PhD Studentship, King’s College Hospital Charity, UK. R Liberal is supported by a Doctoral Grant from the Science and Technology Foundation, Science and Higher Education Ministry, Portugal. MS Longhi was supported by the Roger Dobson Fund, King’s College Hospital Charity, UK when this project was started and she is currently supported by a Clinician Scientist Fellowship from the Medical Research Council, UK.

Abbreviations: ADP, adenosine diphosphate; AIH, autoimmune hepatitis; AMP, adenosine monophosphate; ANA, anti-nuclear antibody; AST, aspartate aminotransferase; ATP, adenosine triphosphate; SMA, smooth muscle antibody; Treg, regulatory T cell

Correspondence:

Dr Maria Serena Longhi, Institute of Liver Studies, King’s College London School of Medicine, 3\(^{\text{rd}}\) Floor Cheyne Wing, King’s College Hospital, Denmark Hill, London, UK, SE5 9RS. Tel: +44(0)2032993397; Fax: +44(0)2032993760; e-mail: maria.longhi@kcl.ac.uk

Disclosures: the authors have nothing to disclose
Abstract

BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is an important cause of severe liver disease and is associated with both quantitative and qualitative regulatory T cell (Treg) impairments. We have shown that Tregs express CD39, an ectonucleotidase responsible for extracellular nucleotide hydrolysis, culminating in the production of immunosuppressive adenosine. In this study, we describe multiple CD39pos Treg defects that potentially contribute to the impaired immuno-regulation that is characteristic of AIH. METHODS: We have examined the frequency and phenotype of CD39pos Tregs by flow cytometry and measured their ectonucleotidase activity. The capacity of CD4posCD25high, CD4posCD25highCD39pos and CD4posCD25highCD39neg subsets to suppress both proliferation of effector T cells and IL17 production was evaluated. RESULTS: In AIH, CD39pos Tregs are decreased in frequency, exhibit limited adenosine triphosphate (ATP)/adenosine diphosphate (ADP) hydrolysis activity and fail to suppress IL17 production by effector CD4 T cells. Moreover, these CD39pos Tregs display a more pro-inflammatory profile in AIH, which is characterised by elevated CD127 positivity, and a greater propensity to produce IFNγ or IL17 upon challenge with pro-inflammatory stimuli. CONCLUSIONS: In AIH CD39pos Tregs are decreased in number, fail to adequately hydrolyse pro-inflammatory nucleotides and do not suppress efficiently IL17 production by effector CD4 T cells. CD39pos Tregs show plasticity and are unstable upon pro-inflammatory challenge, suggesting that defective immuno-regulation in AIH might result not only from reduced Treg number and function but also from increased conversion of Tregs into effector cells.
Introduction

Autoimmune hepatitis (AIH) is an inflammatory disease of the liver, characterised by female preponderance, interface hepatitis on histology, hypergammaglobulinaemia and serum autoantibody positivity(1, 2). Several lines of evidence indicate that in AIH numerical and functional regulatory T cell (Treg) defects are likely to play a permissive pathogenic role, allowing effector CD4 and CD8 T lymphocytes to initiate and perpetuate liver damage(3-5).

The reasons for the Treg functional impairment in AIH are unclear. Previous studies in both mice and humans have highlighted a number of mechanisms used by Tregs to mediate suppression, including the release of anti-inflammatory cytokines and the modulation of antigen presenting cell function.

More recently, metabolic disruption of effector cell function by Tregs has also been explored(6). Central to this mode of suppression is the expression by Tregs of the ectoenzyme CD39, which catalyses the degradation of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) into adenosine monophosphate (AMP). AMP is subsequently converted to the immunomodulatory nucleoside adenosine by CD73, an ectoenzyme that works in tandem with CD39(7-9).

At variance with the murine setting, CD39 in humans is expressed not only by conventional Tregs but also by cytokine - i.e. IL4, IL5, IL17 and IFNγ - producing effector memory cells(8, 10). Again unlike mice, CD73 is poorly expressed by human Tregs, suggesting that in humans AMP conversion to adenosine is mediated by paracrine mechanisms or by the presence of CD73 on target or neighbouring cells(10).

Compared to their CD39neg counterpart, CD39pos Tregs have been shown to be phenotypically stable upon pro-inflammatory challenge(10) and to display preferential suppression over Th17 immunity(11).

Defective numbers of CD39pos Tregs have been reported in patients with multiple sclerosis(8, 11), where these cells are also impaired in their ability to suppress IL17 production(11). Defective CD39pos Treg function has been also described in systemic lupus erythematosus(12). Additionally, the
presence of a CD39 single nucleotide polymorphism has been reported in Crohn’s disease and found to be associated with low CD39 mRNA expression levels and disease susceptibility(13).

Given the key role of CD39 in governing Treg suppressive function, we aimed to explore whether the impairment of Tregs, previously observed in AIH, resided in alterations of CD39 expression. To this end, we investigated the frequency, phenotypic and functional signature of CD39^{pos} Tregs in AIH as well as their stability upon pro-inflammatory challenge, a feature particularly relevant to the development of immunotherapeutic strategies aimed at reconstituting immuno-tolerance through Treg adoptive transfer.
Patients and methods

Patients and controls

Forty-one patients with anti-nuclear and/or anti-smooth muscle antibody positive AIH (25 female) were studied. At the time of, or close to diagnosis a liver biopsy showed interface hepatitis in all. Patients with bile duct changes characteristic of sclerosing cholangitis on retrograde cholangiography were excluded from analysis. The median age of patients included in the study was 14 years (range 6-27 years). Of fourteen patients with active disease, defined by the presence of abnormal aspartate aminotransferase (AST) levels, three were studied before immunosuppressive treatment was started. Twenty-seven patients were studied during drug-induced remission (defined by normalisation of AST levels). Treatment consisted of prednisolone (5-15mg/day) with or without azathioprine (25-150mg/day) or mycophenolate mofetil (MMF; 500-2000mg/day, n=10). Demographic and biochemical data are shown in Table 1. Eight subjects with liver disorders of non-autoimmune and non-viral aetiology served as disease control patients (DC) (7 females, median age 15 years [range 6-25 years]). Of this group, two patients had non-alcoholic fatty liver disease (NAFLD), one α-1 antitrypsin deficiency, one Gilbert syndrome, one Wilson disease, one congenital portosystemic shunt, one Alagille syndrome and one hepatic adenoma. Twenty-five healthy subjects (HS) served as normal controls (15 females, median age 35 years [range 22-50 years]). The age difference between AIH/DC patients and HS derived from ethical constraints in obtaining blood from healthy children. The study was approved by the ethical committee of King’s College Hospital, London and written consent was obtained from each AIH patient and HS enrolled in the study.

Cell separation

Peripheral blood mononuclear cells (PBMCs) were isolated as described previously (3). Viability of mononuclear cells, determined by trypan blue exclusion, exceeded 98%.

Flow cytometry
PBMCs were stained with allophycocyanin (APC) cyochrome-7 (Cy7)-conjugated anti-CD4, APC-conjugated anti-CD73, phycoerythrin (PE)-Cy7-conjugated anti-CD39 (all eBioscience, Hatfield, UK), PE-conjugated anti-CD25, fluorescein isothiocyanate (FITC)-conjugated anti-CD127, PE-conjugated anti-CD45RO and FITC-conjugated anti-CD62L (all BD Biosciences, Discovery Labware, Oxford, UK) monoclonal antibodies. Cells were incubated at 4°C in the dark for 30 minutes and washed with phosphate buffered saline (PBS) supplemented with 1% foetal calf serum (FCS) before analysis by flow cytometry on a Becton Dickinson fluorescence activated cell sorter (FACS-Canto™ II, Beckton Dickinson Immunocytochemistry Systems, San Jose, CA). FACSDiva software was used for analysis. The percentage of cells positive for FOXP3 or intracellular CD152 was determined after fixation and permeabilisation with Cytofix/Cytoperm™ (BD Biosciences) and the addition of APC-conjugated anti-FOXP3 (eBioscience) or APC-conjugated anti-CD152 (BD Biosciences) monoclonal antibodies.

The percentage of IFNγ, IL17, IL10 and transforming growth-factor β (TGFβ)-positive cells was determined after exposure to phorbol 12-mystrate 13-acetate (10ng/mL) and ionomycin (500ng/mL; both Sigma Aldrich, Gillingham, UK) and following addition of brefeldin-A (10µg/mL; Sigma Aldrich) for 5 hours. Cells were then stained using PE-conjugated anti-IFNγ, PE-conjugated anti-IL10 (both BD Biosciences), FITC-conjugated anti-IL17 (eBioscience) or Peridinin chlorophyll protein complex (PerCP)-conjugated anti-TGFβ (R&D Systems, Abingdon, UK).

**Cell stimulation**

PBMCs were seeded at $1 \times 10^6$ cells/ml in 96-well round-bottom plates in RPMI-1640 pre-supplemented with 2mM L-glutamine and 1% Antibiotic-Antimycotic solution (both from Gibco, Invitrogen, Paisley, UK) and 10% FCS. Cells were exposed to anti-CD3/anti-CD28 T cell expander (ratio bead/cell: 1/2; Dynal Invitrogen, Oslo, Norway) and recombinant human IL-2 (30U/mL; EuroCetus; Amsterdam, Netherlands), a protocol chosen on the basis of previous experiments(14). To test whether the phenotype of CD39<sup>pos</sup> Tregs remained stable upon pro-inflammatory challenge, cells were treated with recombinant human IL6 (0.04µg/mL) and IL1β (0.01µg/mL; both R&D Systems)
and cultured at 37°C and 5% CO₂ for 5 days. Cells were washed in PBS/1% FCS and flow cytometry was performed as above.

**Cell purification**

For co-culture assays, CD4⁺ cells were isolated from the total PBMC population using immunomagnetic beads (Dynal Invitrogen) as described(3, 14). CD4⁺ T cells were then stained with FITC- or APC-Cy7-conjugated anti-CD4 (eBioscience), APC- or PE-conjugated anti-CD25 (BD Bioscences) and PE- or PE-Cy7-conjugated CD39 (eBioscience). The CD4⁺ cells were then sorted into CD25<sup>high</sup>, CD25<sup>high</sup>CD39<sup>pos</sup> (CD39<sup>pos</sup> Tregs), CD25<sup>high</sup>CD39<sup>neg</sup> (CD39<sup>neg</sup> Tregs) and CD25<sup>neg</sup> subsets by fluorescence activated cell sorting (FACS) using a Becton Dickinson cell sorter (FACSAria™ II; Beckton Dickinson Immunocytochemistry Systems). The purity of the CD25<sup>high</sup>, CD25<sup>high</sup>CD39<sup>pos</sup> and CD25<sup>high</sup>CD39<sup>neg</sup> populations exceeded 95% and the purity of the CD25<sup>neg</sup> cells exceeded 98%.

For experiments assessing CD39 enzymatic activity, CD4⁺CD25<sup>pos</sup> and CD4⁺CD25<sup>neg</sup> populations were isolated immunomagnetically as described previously(3, 14). The purity of immunomagnetically isolated populations exceeded 85%.

**Measurement of enzymatic activity**

The enzymatic activity of immunomagnetically isolated CD4⁺CD25<sup>neg</sup> and CD4⁺CD25<sup>pos</sup> cells was measured indirectly by quantifying the concentration of free phosphate using the colorimetric Sensolyte® malachite green phosphate assay kit (AnaSpec, Seraing, Belgium). Populations were washed in saline solution containing 0.9% w/v NaCl – to remove residual phosphate-containing media – and plated at 2×10⁵ cells/ml, before exposure to 10µM ATP (Sigma Aldrich, Gillingham, UK) for 15 minutes. Phosphate concentration was quantified at 600nm using an absorbance plate reader after comparison with a standard curve.

Thin layer chromatography (TLC) was performed as described previously(7), to visualise the hydrolysis of radiolabeled ADP to AMP and its subsequent conversion to adenosine. 2.5×10⁵
immunomagnetically isolated CD4^{pos}CD25^{pos} or CD4^{pos}CD25^{neg} cells were exposed to 2mCi/ml [C^{14}] ADP (Perkin Elmer, Cambridge, UK) in the presence of 10mM Ca^{2+} and 5mM Mg^{2+}. Aliquots were collected at reaction-times of 5, 10, 20, 40 and 60 minutes before analysis of [C^{14}]ADP hydrolysis products by TLC. Samples were loaded onto silica gel matrix plates (Sigma Aldrich, Gillingham, UK) and [C^{14}]ADP derivatives were separated using an appropriate solvent mixture(15).

*Co-culture assays*

Once purified, the CD25^{neg} responder cell populations were seeded overnight in 96-well round-bottom plates in the presence of anti-CD3/anti-CD28 T cell expander (ratio bead/cell: 1/2 Dynal Invitrogen) and recombinant human IL2 (30 U/mL; EuroCetus). CD25^{high}, CD39^{pos} or CD39^{neg} Tregs were then added to autologous CD25^{neg} responder cells at a ratio of 1/8(14). Parallel cultures of CD25^{neg} responder cells in the absence of Tregs were performed. To analyse the proliferation of effector cells, for the final 18 hours of culture, cells were pulsed with 0.25µCi/well ^3^H-thymidine (Perkin Elmer, Cambridge, UK) and harvested using a multichannel harvester. The amount of incorporated ^3^H-thymidine was measured using a β-counter. In preliminary experiments, in which cells from 4 AIH patients and 4 HS were tested, proliferation was also analysed using the CellTrace™ carboxy fluorescein succinimidyl ester (CFSE) cell proliferation kit (Molecular Probes, Paisley, UK). For analysis of cytokine production, cells were stained with FITC- or APC-Cy7-conjugated anti-CD4, FITC- or PE- conjugated anti-IL17 (all eBioscience) and APC- or PE- conjugated anti-IFNγ (IQ Products, Netherlands, and BD Biosciences) and analysed as described above.

*Statistical analysis*

The normality of variable distribution was assessed by the Kolmogorov-Smirnov goodness of fit test; once the hypothesis of normality was accepted (P<0.05), comparisons were performed using paired or unpaired Student’s t tests for linked or unlinked data respectively. A one-way ANOVA, followed by Tukey’s multiple comparisons test, was used to compare the means of multiple samples. Results are expressed as mean±SEM unless otherwise stated and P values <0.05 were considered significant.
values \textgreater= 0.05 \text{ and } \leq 0.15 \text{ denote a trend to significance. Data were analysed using GraphPad Prism® 5 software (GraphPad; San Diego, CA) and SPSS software (IBM; Hampshire, UK).}
Results

Enumeration and characterisation of CD4\textsuperscript{pos}CD25\textsuperscript{high}CD39\textsuperscript{pos} regulatory T cells

The frequency of circulating CD4\textsuperscript{pos}CD39\textsuperscript{pos} cells was similar in AIH patients, DC patients and HS (9.7±2.7, 10.8±2.4 and 11.1±2.0 respectively, \(P=\text{NS}\)). However, the frequency of CD4\textsuperscript{pos}CD39\textsuperscript{pos}CD25\textsuperscript{high} (hereafter denoted CD39\textsuperscript{pos} Tregs) was markedly reduced in AIH patients compared to DC patients or HS (Figure 1A,B). The frequency of CD39\textsuperscript{pos} Tregs was similar in AIH patients with active and inactive disease (4.2±1.3 vs 3.5±0.7, \(P=\text{NS}\)). Male AIH patients had fewer CD39\textsuperscript{pos} Tregs compared to their female counterparts (2.4±0.6 vs 5.1±0.9, \(P=0.03\)). The difference between males and females was not observed in the HS population (9.4±2.8 vs 6.8±1.8, \(P=\text{NS}\)). To test the influence of age on the frequency of CD39\textsuperscript{pos} Tregs, AIH patients were subdivided into those <13 or \(\geq\)13 years of age. The frequency of CD39\textsuperscript{pos} Tregs did not differ when this comparison was made (4.7±1.4 vs 3.3±0.3, \(P=\text{NS}\)). CD25\textsuperscript{high} cells contained higher proportions of cells positive for CD39 compared to the CD25\textsuperscript{med} and CD25\textsuperscript{neg} populations in HS [CD25\textsuperscript{high}: 43.0±4.8 vs CD25\textsuperscript{med}: 26.0±5.3 (\(P<0.05\)) and vs CD25\textsuperscript{neg}: 14.6±3.2 (\(P<0.001\))], DC patients [CD25\textsuperscript{high}: 46.7±8.4 vs CD25\textsuperscript{med}: 23.4±3.6 (\(P<0.05\)) and vs CD25\textsuperscript{neg}: 15.2±3.5 (\(P<0.01\))] and AIH patients [CD25\textsuperscript{high}: 40.7±4.6 vs CD25\textsuperscript{med}: 22.8±3.8 (\(P<0.05\)) and vs CD25\textsuperscript{neg}: 12.6±2.6 (\(P<0.001\))]. In AIH patients, DC patients and HS, the frequency of CD4\textsuperscript{pos}CD39\textsuperscript{pos} cells positive for FOXP3 was greater in the CD25\textsuperscript{high} subset compared to the CD25\textsuperscript{med} or CD25\textsuperscript{neg} populations (Figure 1C).

AIH patients treated with prednisolone and MMF had a lower frequency of CD39\textsuperscript{pos} Tregs compared to those treated with prednisolone alone (5.6±1.9 vs 1.7±0.5, \(P=0.01\)) or with prednisolone and azathioprine (4.7±1.1 vs 1.7±0.5, \(P=0.03\)).

Compared to HS and DC patients (Table 2), CD39\textsuperscript{pos} Tregs from AIH patients contained a lower frequency of cells negative for CD127 – the lack of which distinguishes \textit{bona fide} Tregs from effector T cells\,(16, 17) \(–\), lower proportions of cells positive for the memory cell marker CD45RO and a similar frequency of cells positive for the Treg function-associated markers FOXP3, CD152 or CD62L. Approximately 10\% of CD39\textsuperscript{pos} Tregs expressed CD73 in AIH patients, DC patients and HS.
The frequency of CD127<sup>neg</sup> cells within CD39<sup>pos</sup> Tregs tended to be lower in patients with active disease compared to those studied during remission (Table 2).

The frequency of CD39<sup>pos</sup> Tregs producing the pro-inflammatory cytokines IFNγ and IL17 or the anti-inflammatory cytokines TGFβ or IL10 was similar in AIH patients, DC patients and HS (Table 2).

Given that the frequency and the phenotype profile of CD39<sup>pos</sup> Tregs in HS and DC patients were comparable, only cells from HS were used for the following experimental sections.

**Phenotypic stability of CD39<sup>pos</sup> regulatory T cells**

After stimulation of PBMCs with anti-CD3/anti-CD28 T cell expander (Table 3a), the frequency of CD39<sup>pos</sup> Tregs positive for FOXP3 or CD127 increased to a similar extent in AIH patients and HS. The frequency of CD73<sup>pos</sup> CD39<sup>pos</sup> Tregs decreased and the frequency of CD45RO<sup>pos</sup> CD39<sup>pos</sup> Tregs increased in HS, while remaining unchanged upon stimulation in AIH patients. The frequencies of IFNγ and IL17-producing cells within CD39<sup>pos</sup> Tregs remained stable in HS, while increased in AIH upon stimulation. The increase in the frequency of CD39<sup>pos</sup> Tregs expressing IL17 or IFNγ was greater in AIH patients compared to HS (Table 3a).

Interestingly, in AIH the size of the increase in frequency of IFNγ<sup>pos</sup> CD39<sup>pos</sup> Tregs correlated with serum AST concentration (r²=0.82, P<0.05).

Exposure of PBMCs to IL1β and IL6 (Table 3b) increased the frequency of FOXP3<sup>pos</sup> CD39<sup>pos</sup> Tregs in HS but not AIH patients, but had no effect on the frequency of CD39<sup>pos</sup> cells expressing CD127 or CD45RO. The frequency of CD73<sup>pos</sup> CD39<sup>pos</sup> Tregs decreased significantly in HS, while it increased in AIH patients, though not significantly. While the frequency of CD39<sup>pos</sup> Tregs producing IFNγ increased to a similar extent in both AIH patients and HS, the frequency of those producing IL17 increased in AIH but remained stable in health.

**ATP/ADP hydrolysis**
Immunomagnetically isolated CD4^{pos}CD25^{pos} Tregs from AIH patients were less able to hydrolyse exogenous ATP compared to HS (Figure 2A). In HS, but not AIH patients, the CD25^{pos} cells generated greater concentrations of phosphate compared to CD25^{neg} cells (Figure 2A), as and this was reflected by higher CD39 expression on a population (3.65±0.40 vs 24.53 ±4.61, P=0.002) and per-cell basis, the latter expressed as mean fluorescence intensity (2239±147 vs 2901±213, P=0.059).

Analysis of [C^{14}]-radiolabelled ADP hydrolysis by TLC (Figure 2B) revealed that CD4^{pos}CD25^{pos} cells from HS were able to hydrolyse ADP into AMP and, at the longer reaction time of 60 minutes, these cells could generate extracellular nucleosides.

In contrast, AMP generation was less pronounced in CD4^{pos}CD25^{pos} cells from AIH patients. CD4^{pos}CD25^{neg} cells in health and AIH degraded ADP less efficiently than the CD4^{pos}CD25^{pos} populations, failing to produce extracellular adenosine.

Suppressive ability of CD39^{pos} Tregs

Preliminary experiments, in which both ^{3}H-thymidine and CFSE were used to analyse the suppressive ability of immunomagnetically isolated CD4^{pos}CD25^{pos} cells, confirmed reports (3, 4, 14) that Tregs from AIH patients are less able to suppress the proliferation of autologous CD4^{pos}CD25^{neg} responder cells compared to HS (Supplementary Figure 1). As CFSE- and ^{3}H-thymidine-based assays gave comparable results, given the requirement for fewer cells, ^{3}H-thymidine was used to measure the proliferation of FACS sorted populations, which had comparatively low yield compared to those magnetically isolated.

CD4^{pos}CD25^{high} Tregs from HS and AIH patients and CD39^{neg} Tregs from HS were able to suppress the proliferation of responder T cells (one-sample t-tests when comparing suppression in the presence and absence of Tregs; P=0.04, P=0.04, P=0.05 respectively. Percent suppression of proliferation by CD25^{high} cells was lower in AIH patients than in HS. In HS, CD39^{pos} Tregs were poor suppressors of proliferation compared to conventional CD4^{pos}CD25^{high} Tregs and CD39^{neg} Tregs (Figure 3A).
In HS, CD4\textsuperscript{pos}CD25\textsuperscript{high}, CD39\textsuperscript{pos} and CD39\textsuperscript{neg} Tregs were able to suppress the production of IL17 (one sample \textit{t}-tests; \textit{P}=0.001, \textit{P}=0.01, \textit{P}=0.007 respectively), while in AIH, only the CD25\textsuperscript{high} population was able to suppress IL17 production (one sample \textit{t}-test; \textit{P}=0.006). Both the CD25\textsuperscript{high} and CD39\textsuperscript{pos} Tregs were less able to suppress IL17 production in AIH patients compared to HS (Figure 3B).
Discussion

In the current study we show that Tregs expressing the ectonucleotidase CD39 are present at low levels and are also dysfunctional in AIH.

Phenotypic analysis has indicated that the expression of CD39 is associated with classical Treg features, i.e. high CD25 and FOXP3 and low CD127 expression. CD39\textsuperscript{pos} Tregs effectively suppress CD4 T cell IL17 production while exerting poor control over target cell proliferation, suggesting that this Treg subgroup may have a specific role in dampening Th17 immunity. Low frequencies of CD39\textsuperscript{pos} Tregs and inability to control adequately IL17 mediated immuno-reactivity have been described also in patients with MS (8, 11). Moreover, low CD39 expression has been reported in IBD, where it is associated to a CD39 polymorphism (13), suggesting a genetically encoded defect of immune regulation in this condition. Future studies should explore whether CD39 polymorphisms account for the observed Treg/effecter cell imbalance in AIH, and therefore contribute to disease initiation and/or perpetuation.

A comparison between health and disease has revealed that CD39\textsuperscript{pos} Tregs from AIH patients are impaired in number, in their ability to hydrolyse ATP and ADP and in their suppressive function, indicating that in AIH CD39\textsuperscript{pos} Treg impairment occurs at multiple levels.

A potential limitation of this study is the use of a heterogenous AIH population, including patients under different treatment regimens. This has been overcome to some extent by the size of the patient group which has enabled us to observe interesting and novel associations. We have, for example, noted that the frequency of CD39\textsuperscript{pos} Tregs was markedly decreased in AIH patients receiving prednisolone and MMF compared to those treated with prednisolone alone or in combination with azathioprine, raising the possibility that these treatment regimens differentially impact the frequency of this regulatory T cell subset. Alternatively, the lower CD39\textsuperscript{pos} Treg frequencies observed in the MMF treated group may reflect the fact that these patients have a particularly severe form of disease characterised by a more marked impairment in immune-regulation and the mechanisms governing it. Also of note, CD39\textsuperscript{pos} Treg defects were particularly pronounced in male AIH patients. Since this
gender difference was not observed in healthy subjects, it is possible that hormonal differences, particularly the presence of oestrogen, can partially overcome the CD39\textsuperscript{pos} Treg defect in AIH.

In AIH patients, particularly in those with active disease, CD39\textsuperscript{pos} Tregs contain low proportions of CD127\textsuperscript{neg} lymphocytes, suggesting that CD39\textsuperscript{pos} Tregs from AIH patients, in addition to being numerically defective, are also skewed towards a pro-inflammatory profile. Lower CD127\textsuperscript{neg} cell frequencies within CD39\textsuperscript{pos} Tregs are paralleled by lower proportions of CD45RO\textsuperscript{pos} cells. Though the reasons for the CD45RO decrease are unclear, it should be recalled that in humans CD39 is mainly expressed on memory cells(10); therefore low frequencies of CD45RO\textsuperscript{pos} lymphocytes may reflect the numerical CD39\textsuperscript{pos} Treg impairment.

In AIH, CD39\textsuperscript{pos} Tregs are also less able to hydrolyse ATP and ADP, this defect ultimately resulting in reduced production of AMP and immunosuppressive adenosine. Persistently high levels of pro-inflammatory ATP and ADP may contribute to the perpetuation of inflammation. Inefficient CD39 hydrolytic activity is likely to account for the decreased ability of Tregs to control CD4 effector cell function, in particular the production of IL17, which is involved in AIH liver damage(18, 19).

Expression of CD39 has previously been linked to Treg lineage stability(10, 11). Characterisation of CD39\textsuperscript{pos} Treg phenotype before and after stimulation with anti-CD3/anti-CD28, a classical T cell stimulus, and with IL6 and IL1\textbeta, cytokines mimicking the pro-inflammatory environment in AIH, has shown that CD39\textsuperscript{pos} Tregs from AIH patients are less stable than in health, as they undergo a marked increase in the production of IL17 and IFN\gamma. These data suggest that Treg impairment in AIH might derive from an increased rate of Treg conversion into effector cells (Figure 4).

Of note, in contrast to HS, CD73 expression by CD39\textsuperscript{pos} Tregs in AIH patients remained elevated after pro-inflammatory challenge. That CD73 is strictly linked to activation was previously shown in a study by Doherty et al, who reported high CD73 expression levels on CD4 T cells from Crohn’s patients with more active disease(20).
The findings of a reduced stability of CD39\textsuperscript{pos} Tregs in AIH patients should be taken into consideration when developing immunotherapeutic strategies aimed at re-establishing immune-homeostasis through adoptive Treg transfer. Thus, protocols for Treg expansion should include treatment with agents/molecules (e.g., retinoic acid and/or rapamycin) aimed at boosting Treg properties while inhibiting their conversion to pathogenic Th1 and Th17 effector cells. Since CD39\textsuperscript{pos} Tregs exhibit potent IL17-suppressive properties in health, possible mechanisms for boosting CD39 expression in AIH should be explored. A potential candidate is retinoic acid, which is able to boost CD39 expression by naïve T cells (Robson, unpublished observation).

Previous investigations have shown accumulation of CD39\textsuperscript{pos} Tregs in the liver of patients with chronic hepatitis B infection (21). In the experimental cancer setting, hepatic growth of melanoma metastases is inhibited in CD39\textsuperscript{null} mice, while CD39\textsuperscript{pos} T-regs inhibit anti-tumour immunity (22). Future studies should examine the frequency and the tissue localisation of liver infiltrating CD39\textsuperscript{pos} Tregs in AIH and explore whether defective CD39 expression by circulating Tregs is also reflected in the inflamed liver. These findings would have important implications for the development of adoptive Treg therapy for AIH.

In conclusion, this study has shown that in AIH there is a numerical decrease in CD39\textsuperscript{pos} Tregs. These CD39\textsuperscript{pos} Tregs are impaired in their enzymatic and suppressive abilities and, upon pro-inflammatory challenge, are less stable than in health. Defective immune-regulation in AIH may derive not only from impaired Treg number and function but also from an increased rate of Treg conversion into effector cells.

**Acknowledgements**

The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King’s College Hospital NHS Foundation Trust.
Legends to figures

Figure 1. Characterisation of CD39\textsuperscript{pos} Tregs. (A) Frequency of CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{high}}CD39\textsuperscript{pos} Tregs in one representative autoimmune hepatitis (AIH) patient, one disease control (DC) patient and one healthy subject (HS). Plots show gated CD4\textsuperscript{pos} lymphocyte populations. (B) Frequency of CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{high}}CD39\textsuperscript{pos} Tregs in 31 AIH patients, 8 DC patients and 25 HS. (C) Frequency of FOXP3\textsuperscript{pos} cells within CD4\textsuperscript{pos}\textsuperscript{CD39\textsuperscript{pos}}CD25\textsuperscript{high}, CD4\textsuperscript{pos}\textsuperscript{CD39\textsuperscript{pos}}CD25\textsuperscript{med} and CD4\textsuperscript{pos}\textsuperscript{CD39\textsuperscript{pos}}CD25\textsuperscript{low} populations in 31 AIH patients, 8 DC patients and 25 HS.

Figure 2. CD39 enzymatic activity of Tregs in AIH and HS. (A) Ability of immunomagnetically isolated CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{pos}} and CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{neg}} cells from 3 autoimmune hepatitis (AIH) patients and 4 healthy subjects (HS) to produce free phosphate – the bi-product of ATP hydrolysis – after the addition of exogenous ATP. (B) CD39 ADPase enzymatic activity of immunomagnetically isolated CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{pos}} and CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{neg}} cells was assessed by thin layer chromatography at 5, 10, 20, 40 and 60 minute time-points following incubation with 14C-radiolabelled ADP substrate. Image representative of 3 independent experiments.

Figure 3. Suppressive ability of CD39\textsuperscript{pos} Tregs. The ability of FACS-sorted CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{high}}, CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{high}}CD39\textsuperscript{pos} and CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{high}}CD39\textsuperscript{neg} Treg populations to suppress the proliferation (A) or IL17 production (B) of CD4\textsuperscript{pos}\textsuperscript{CD25\textsuperscript{neg}} responder cells. For suppression of proliferation, data refer to 4 healthy subjects (HS) and 4 autoimmune hepatitis (AIH) patients. For suppression of IL17 production, data refer to 6 HS and 10 AIH patients.

Figure 4. Impairment of CD39\textsuperscript{pos} Tregs in AIH. In health, CD39\textsuperscript{pos} Tregs produce adenosine and adequately control autoreactive T cell effector functions. In AIH, multiple CD39\textsuperscript{pos} Treg defects – a reduction in frequency, an inability to suppress IL17 production by effector cells, and a propensity to convert to IFN\textgamm or IL17 producing effectors – contribute to impaired immunosuppression and autoimmune liver damage.
References


